SOPHiA GENETICSTM is excited to be a part of the European Society of Medical Oncology 2022 annual meeting, held in person and virtually in Paris, France from September 9-13.
You will have the chance to chat with our experts at booth #258 and schedule a demo universal SOPHiA DDM™ Platform.
Join us on September 10 from 17h-19h in Hall 5 Room 512 for a presentation on our CE-IVD certified SOPHiA DDMTM Dx Oncology Applications
Decentralized in vitro diagnostic testing for new biomarkers in ovarian and lung cancer – homologous recombination deficiency (HRD) and RNA fusion detection.
What’s New? CE-IVD Oncology Applications by SOPHiA GENETICS™
Alexander Kurze, PhD
Senior Director Product Management, SOPHiA GENETICS
Evaluation of a low-pass whole genome sequencing-based solution for homologous recombination deficiency detection supported by deep learning algorithms
Dr. Adrien Buisson
Praticien Spécialiste des CLCC – UF de Biologie des Tumeurs, Centre Léon Bérard- Cheney
Clinical validation of novel RNA fusion detection for NSCLC with SOPHiA DDMTM Dx RNAtarget Oncology Solution
Prof. Alexander Harlé, PhD
Biologist/Professor of liquid biopsy and tumor heterogeneity group, Institut de Cancérologie de Lorraine-Alexis Vautrin
Enabling clinical workflows in Trusted Research Environments
Gaetano Bonifacio, PhD
Industry Advisor-Healthcare, Microsoft